TICKERNERD
Menu
GOSSGOSSHealthcare · Biotechnology

GOSS Stock Forecast: Gossamer Bio, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$11
−0.56% on the day

The 7 Wall Street analysts covering Gossamer Bio, Inc. hold a median 12-month price target of $90 — +745.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 3 Oct 2026 — in the upper half.

Market cap
$65.5M
Ticker Nerd rank
50 / 100
Median analyst target
$90
Analysts covering
7
Revenue$9.2M−19.6% y/y
Operating income−$26.1M
Net income$16.9M
Free cash flow−$39.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
−23.9%
YTD
−95.7%
1Y
−94.8%
From 52W high
−96.5%
From 52W low
+2.6%
$10
$303
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GOSS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Gossamer Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
79
Revisions
73
Issuance
63
Growth
60
Value
60
Accruals
57
Quality
21
Volatility
16
Momentum
8

Size (79): Smaller than most of the companies we track.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GOSS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GOSS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$100$200$300Jan 26Apr 26Jul 26Oct 26GOSSHigh $120Median $90Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
3 Buy3 Hold1 Sell
Low $22Median $90High $120

The green dot is the last close — the median target sits +745.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
21 Sept 2026HC Wainwright & Co.MaintainsBuy$2.00 → $90
14 Aug 2026Piper SandlerMaintainsOverweight$15 → $4.00
14 Aug 2026Piper SandlerMaintainsOverweight—
28 July 2026Leerink PartnersUpgradeOutperform$1.00
28 July 2026Leerink PartnersUpgradeOutperform—
27 July 2026HC Wainwright & Co.ReiteratesBuy$2.00
27 July 2026HC Wainwright & Co.ReiteratesBuy—
25 June 2026HC Wainwright & Co.MaintainsBuy$5.00 → $2.00
25 June 2026HC Wainwright & Co.MaintainsBuy—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
19 May 2026BarclaysMaintainsUnderweight—
23 Mar 2026Cantor FitzgeraldDowngradeNeutral—
6 Mar 2026HC Wainwright & Co.MaintainsBuy—
5 Mar 2026OppenheimerMaintainsOutperform—
24 Feb 2026BarclaysDowngradeUnderweight—
24 Feb 2026Leerink PartnersDowngradeMarket Perform—
24 Feb 2026WedbushDowngradeNeutral—
28 Jan 2026BarclaysInitiatesOverweight—
22 Jan 2026HC Wainwright & Co.ReiteratesBuy—
11 Sept 2025Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GOSS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GOSS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Gossamer Bio, Inc. returned −94.8% against +16.2% for the S&P 500, dividends included.

GOSS vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26GOSSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GOSS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Gossamer Bio, Inc. (GOSS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
1.2×

Cheaper than 64% of US stocks

Price / book
−0.5×

Cheaper than 94% of US stocks

EV / EBITDA
−0.3×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
−19.6%

Higher than 12% of US stocks

Earnings growth (YoY)
−19.6%

Higher than 21% of US stocks

Gross margin
—
Operating margin
−282.2%

Higher than 9% of US stocks

Net margin
−235.0%

Higher than 2% of US stocks

Returns & dividend
Return on equity
138.8%

Higher than 97% of US stocks

Return on assets
−62.4%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Gossamer Bio, Inc. (GOSS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Gossamer Bio, Inc. has a market value of $65.5M and an enterprise value of $48.5M.

  • Revenue in the twelve months to 30 June 2026: $53.3M. The latest quarter shrank 19.6% year on year.

  • Net income over the same four quarters: −$125.2M, a −235.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−56.00.

  • Free cash flow in the twelve months to 30 June 2026: −$162.6M.

  • Shares outstanding: 6.1M.

  • Trailing P/E: −0.2×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Gossamer Bio, Inc. employs 161 people — $331K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

GOSS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GOSSGossamer Bio, Inc.$65.5M
50
HRTXHeron Therapeutics, Inc.$66.0M
45
GUTSFractyl Health, Inc.$64.5M
30
XBITXBiotech, Inc.$66.8M
32
PLRXPliant Therapeutics, Inc.$64.1M
67
SPROSpero Therapeutics, Inc.$67.0M
89
FBIOFortress Biotech, Inc.$67.4M
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Gossamer Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GOSS news & analysis

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Business Wire · 23 Sept 2026positive

Gossamer Bio announced that it submitted a New Drug Application to the U.S. FDA in September 2026 for seralutinib, its candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Why it matters — This NDA submission represents a significant regulatory milestone for Gossamer's lead candidate, seralutinib, moving the company's main pipeline program closer to potential approval.

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Business Wire · 16 Sept 2026neutral

Gossamer Bio announced the appointment of Greg Ciongoli to its Board of Directors, effective September 16, 2026, where he will also serve as a member of the Audit Committee. The company is a clinical-stage biopharmaceutical firm focused on developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Why it matters — A GOSS watcher would care because the addition of an experienced director, particularly on the Audit Committee, affects the company's corporate governance as it advances its clinical-stage pipeline.

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Business Wire · 11 Sept 2026neutral

Gossamer Bio announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State to effect a 1-for-80 reverse stock split of its common stock. The reverse split is now effective.

Why it matters — A reverse stock split is a corporate action that reduces the number of outstanding shares and typically raises the per-share price, which can affect how GOSS shares are traded and perceived.

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Business Wire · 9 Sept 2026neutral

Gossamer Bio announced that its board of directors has selected a 1-for-80 reverse stock split of the Company's common stock, along with a proportionate reduction in the number of shares. The company is a clinical-stage biopharmaceutical firm focused on seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Why it matters — GOSS watchers would care because a reverse stock split can affect share price, share count, and market perception of the company's stock.

Gossamer Bio to Present at Cantor Global Healthcare Conference

Business Wire · 4 Sept 2026neutral

Gossamer Bio announced it will present at the Cantor Global Healthcare Conference scheduled for September 9-11, 2026. The company is a clinical-stage biopharmaceutical firm developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Why it matters — A conference presentation offers GOSS watchers an opportunity to hear the company update on its seralutinib clinical programs and strategic outlook.

FAQ

Frequently asked questions about GOSS stock

What is the GOSS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Gossamer Bio, Inc. have a median 12-month price target of $90, with estimates ranging from $22 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GOSS stock a buy right now?

Of the 7 analysts covering Gossamer Bio, Inc., 3 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Gossamer Bio, Inc. 50 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GOSS?

As at 3 Oct 2026, Gossamer Bio, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will GOSS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +745.1% from the last close, and Ticker Nerd's factor model ranks Gossamer Bio, Inc. 50 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GOSS stock forecast for 2030?

No analyst covering Gossamer Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GOSS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $120 over the next 12 months.

How has GOSS stock performed over the past year?

Gossamer Bio, Inc. returned -94.8% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Gossamer Bio, Inc. do?

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary and inflammatory diseases.

What is the latest news on GOSS?

The most recent item we track (Business Wire, 23 Sept 2026): "Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension". Gossamer Bio announced that it submitted a New Drug Application to the U.S. FDA in September 2026 for seralutinib, its candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Company

About Gossamer Bio, Inc.

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary and inflammatory diseases. Its lead product candidate, seralutinib, is being studied for pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company also works on other drug candidates for immune-driven and respiratory conditions, using an approach centered on discovering and advancing targeted treatments. Gossamer Bio Inc. plays a specialized role in the healthcare market by addressing serious diseases with significant unmet medical need through its research, development, and clinical trial programs. The company is headquartered in San Diego, California.

CEO Mr. Faheem Hasnain · 161 employees · United States · https://www.gossamerbio.com